Laryngeal and Pharyngeal Squamous Cell Carcinoma After Antireflux Surgery in the 5 Nordic Countries

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Laryngeal and Pharyngeal Squamous Cell Carcinoma After Antireflux Surgery in the 5 Nordic Countries. / Yanes, Manar; Santoni, Giola; Maret-Ouda, John; Ness-Jensen, Eivind; Farkkila, Martti; Lynge, Elsebeth; Pukkala, Eero; Romundstad, Pal; Tryggvadottir, Laufey; von Euler-Chelpin, My; Lagergren, Jesper.

In: Annals of Surgery, Vol. 276, No. 2, 2022, p. E79-E85.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Yanes, M, Santoni, G, Maret-Ouda, J, Ness-Jensen, E, Farkkila, M, Lynge, E, Pukkala, E, Romundstad, P, Tryggvadottir, L, von Euler-Chelpin, M & Lagergren, J 2022, 'Laryngeal and Pharyngeal Squamous Cell Carcinoma After Antireflux Surgery in the 5 Nordic Countries', Annals of Surgery, vol. 276, no. 2, pp. E79-E85. https://doi.org/10.1097/SLA.0000000000004423

APA

Yanes, M., Santoni, G., Maret-Ouda, J., Ness-Jensen, E., Farkkila, M., Lynge, E., Pukkala, E., Romundstad, P., Tryggvadottir, L., von Euler-Chelpin, M., & Lagergren, J. (2022). Laryngeal and Pharyngeal Squamous Cell Carcinoma After Antireflux Surgery in the 5 Nordic Countries. Annals of Surgery, 276(2), E79-E85. https://doi.org/10.1097/SLA.0000000000004423

Vancouver

Yanes M, Santoni G, Maret-Ouda J, Ness-Jensen E, Farkkila M, Lynge E et al. Laryngeal and Pharyngeal Squamous Cell Carcinoma After Antireflux Surgery in the 5 Nordic Countries. Annals of Surgery. 2022;276(2):E79-E85. https://doi.org/10.1097/SLA.0000000000004423

Author

Yanes, Manar ; Santoni, Giola ; Maret-Ouda, John ; Ness-Jensen, Eivind ; Farkkila, Martti ; Lynge, Elsebeth ; Pukkala, Eero ; Romundstad, Pal ; Tryggvadottir, Laufey ; von Euler-Chelpin, My ; Lagergren, Jesper. / Laryngeal and Pharyngeal Squamous Cell Carcinoma After Antireflux Surgery in the 5 Nordic Countries. In: Annals of Surgery. 2022 ; Vol. 276, No. 2. pp. E79-E85.

Bibtex

@article{d8d5bff9b99d4eb9b8f1c5381839b469,
title = "Laryngeal and Pharyngeal Squamous Cell Carcinoma After Antireflux Surgery in the 5 Nordic Countries",
abstract = "Objective: The aim of this study was to clarify whether antireflux surgery prevents laryngeal and pharyngeal squamous cell carcinoma. Summary Background Data: Gastroesophageal reflux disease (GERD) seems to increase the risk of laryngeal and pharyngeal squamous cell carcinoma. Methods: All-Nordic (Denmark, Finland, Iceland, Norway, and Sweden) population-based cohort study of adults with documented GERD in 1980 to 2014. First, cancer risk after antireflux surgery was compared to the expected risk in the corresponding background population by calculating standardized incidence ratios (SIRs) with 95% confidence intervals (CIs). Second, cancer risk among antireflux surgery patients was compared to nonoperated GERD patients using multivariable Cox regression, providing hazard ratios (HR) with 95% CIs, adjusted for sex, age, calendar period, and diagnoses related to tobacco smoking, obesity, and alcohol overconsumption. Results: Among 814,230 GERD patients, 47,016 (5.8%) underwent antireflux surgery. The overall SIRs and HRs of the combined outcome laryngeal or pharyngeal squamous cell carcinoma (n=39) were decreased after antireflux surgery [SIR=0.62 (95% CI 0.44-0.85) and HR=0.55 (95% CI 0.38-0.80)]. The point estimates were further decreased >10 years after antireflux surgery [SIR=0.48 (95% CI 0.26-0.80) and HR=0.47 (95% CI 0.26-0.85)]. The risk estimates of laryngeal squamous cell carcinoma were particularly decreased >10 years after antireflux surgery [SIR=0.28 (95% CI 0.08-0.72) and HR=0.23 (95% CI 0.08-0.69)], whereas no such decrease over time after surgery was found for pharyngeal squamous cell carcinoma. Analyses of patients with severe GERD (reflux esophagitis or Barrett esophagus) showed similar results. Conclusion: Antireflux surgery may decrease the risk of laryngeal squamous cell carcinoma and possibly also of pharyngeal squamous cell carcinoma.",
keywords = "antireflux medication, fundoplication, gastroesophageal reflux disease, larynx, neoplasm, Nissen, pharynx, proton pump inhibitor, GASTROESOPHAGEAL-REFLUX DISEASE, RISK-FACTOR, LAPAROSCOPIC ANTERIOR, FUNDOPLICATION, ESOPHAGEAL, CANCER, METAANALYSIS, POSTERIOR, REGISTRY, ADENOCARCINOMA",
author = "Manar Yanes and Giola Santoni and John Maret-Ouda and Eivind Ness-Jensen and Martti Farkkila and Elsebeth Lynge and Eero Pukkala and Pal Romundstad and Laufey Tryggvadottir and {von Euler-Chelpin}, My and Jesper Lagergren",
year = "2022",
doi = "10.1097/SLA.0000000000004423",
language = "English",
volume = "276",
pages = "E79--E85",
journal = "Advances in Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams & Wilkins",
number = "2",

}

RIS

TY - JOUR

T1 - Laryngeal and Pharyngeal Squamous Cell Carcinoma After Antireflux Surgery in the 5 Nordic Countries

AU - Yanes, Manar

AU - Santoni, Giola

AU - Maret-Ouda, John

AU - Ness-Jensen, Eivind

AU - Farkkila, Martti

AU - Lynge, Elsebeth

AU - Pukkala, Eero

AU - Romundstad, Pal

AU - Tryggvadottir, Laufey

AU - von Euler-Chelpin, My

AU - Lagergren, Jesper

PY - 2022

Y1 - 2022

N2 - Objective: The aim of this study was to clarify whether antireflux surgery prevents laryngeal and pharyngeal squamous cell carcinoma. Summary Background Data: Gastroesophageal reflux disease (GERD) seems to increase the risk of laryngeal and pharyngeal squamous cell carcinoma. Methods: All-Nordic (Denmark, Finland, Iceland, Norway, and Sweden) population-based cohort study of adults with documented GERD in 1980 to 2014. First, cancer risk after antireflux surgery was compared to the expected risk in the corresponding background population by calculating standardized incidence ratios (SIRs) with 95% confidence intervals (CIs). Second, cancer risk among antireflux surgery patients was compared to nonoperated GERD patients using multivariable Cox regression, providing hazard ratios (HR) with 95% CIs, adjusted for sex, age, calendar period, and diagnoses related to tobacco smoking, obesity, and alcohol overconsumption. Results: Among 814,230 GERD patients, 47,016 (5.8%) underwent antireflux surgery. The overall SIRs and HRs of the combined outcome laryngeal or pharyngeal squamous cell carcinoma (n=39) were decreased after antireflux surgery [SIR=0.62 (95% CI 0.44-0.85) and HR=0.55 (95% CI 0.38-0.80)]. The point estimates were further decreased >10 years after antireflux surgery [SIR=0.48 (95% CI 0.26-0.80) and HR=0.47 (95% CI 0.26-0.85)]. The risk estimates of laryngeal squamous cell carcinoma were particularly decreased >10 years after antireflux surgery [SIR=0.28 (95% CI 0.08-0.72) and HR=0.23 (95% CI 0.08-0.69)], whereas no such decrease over time after surgery was found for pharyngeal squamous cell carcinoma. Analyses of patients with severe GERD (reflux esophagitis or Barrett esophagus) showed similar results. Conclusion: Antireflux surgery may decrease the risk of laryngeal squamous cell carcinoma and possibly also of pharyngeal squamous cell carcinoma.

AB - Objective: The aim of this study was to clarify whether antireflux surgery prevents laryngeal and pharyngeal squamous cell carcinoma. Summary Background Data: Gastroesophageal reflux disease (GERD) seems to increase the risk of laryngeal and pharyngeal squamous cell carcinoma. Methods: All-Nordic (Denmark, Finland, Iceland, Norway, and Sweden) population-based cohort study of adults with documented GERD in 1980 to 2014. First, cancer risk after antireflux surgery was compared to the expected risk in the corresponding background population by calculating standardized incidence ratios (SIRs) with 95% confidence intervals (CIs). Second, cancer risk among antireflux surgery patients was compared to nonoperated GERD patients using multivariable Cox regression, providing hazard ratios (HR) with 95% CIs, adjusted for sex, age, calendar period, and diagnoses related to tobacco smoking, obesity, and alcohol overconsumption. Results: Among 814,230 GERD patients, 47,016 (5.8%) underwent antireflux surgery. The overall SIRs and HRs of the combined outcome laryngeal or pharyngeal squamous cell carcinoma (n=39) were decreased after antireflux surgery [SIR=0.62 (95% CI 0.44-0.85) and HR=0.55 (95% CI 0.38-0.80)]. The point estimates were further decreased >10 years after antireflux surgery [SIR=0.48 (95% CI 0.26-0.80) and HR=0.47 (95% CI 0.26-0.85)]. The risk estimates of laryngeal squamous cell carcinoma were particularly decreased >10 years after antireflux surgery [SIR=0.28 (95% CI 0.08-0.72) and HR=0.23 (95% CI 0.08-0.69)], whereas no such decrease over time after surgery was found for pharyngeal squamous cell carcinoma. Analyses of patients with severe GERD (reflux esophagitis or Barrett esophagus) showed similar results. Conclusion: Antireflux surgery may decrease the risk of laryngeal squamous cell carcinoma and possibly also of pharyngeal squamous cell carcinoma.

KW - antireflux medication

KW - fundoplication

KW - gastroesophageal reflux disease

KW - larynx

KW - neoplasm

KW - Nissen

KW - pharynx

KW - proton pump inhibitor

KW - GASTROESOPHAGEAL-REFLUX DISEASE

KW - RISK-FACTOR

KW - LAPAROSCOPIC ANTERIOR

KW - FUNDOPLICATION

KW - ESOPHAGEAL

KW - CANCER

KW - METAANALYSIS

KW - POSTERIOR

KW - REGISTRY

KW - ADENOCARCINOMA

U2 - 10.1097/SLA.0000000000004423

DO - 10.1097/SLA.0000000000004423

M3 - Journal article

VL - 276

SP - E79-E85

JO - Advances in Surgery

JF - Advances in Surgery

SN - 0003-4932

IS - 2

ER -

ID: 314007671